Physiomics (GB:PYC) has released an update.
Physiomics PLC, a mathematical modelling and data science company, has secured a £186k contract with a major client to provide cancer drug development support using its Virtual Tumour platform. This agreement, which is set to be completed within the current year, propels Physiomics into the next fiscal year with over £0.5m in committed revenues. The company’s expertise in complex therapy modelling has been instrumental in clinching this deal, showcasing its valuable role in the pharmaceutical industry.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
